Molecular Targeted Therapy for Pancreatic Cancer: the End of the Beginning?

11:40 - 12:00, Room 104 (104講堂)

Professor, Graduate Institute of Oncology, 
College of Medicine, National Taiwan University

Deputy director, Department of Oncology, 
National Taiwan University Hospital

Speaker

Professor

Chiun Hsu
MD, PhD

許駿 教授

President of Taiwan pancreas association
Director of Department of Surgery
Chang Gung Memorial Hospital at Linkou, Taiwan

Moderator

Professor

Ta-Sen Yeh

MD, PhD

葉大森 教授

Abstract - 

Molecular targeted therapy for pancreatic cancer: the end of the beginning?

     Development of molecular targeted therapy for pancreatic adenocarcinoma used to be difficult because of the marked molecular heterogeneity and the lack of ‘druggable’ driver mutations in the tumors. Inhibitors of poly-(ADP-ribose) polymerase (PARP) have demonstrated efficacy of prolonging progression-free survival or overall survival as maintenance therapy in many cancer types, and the efficacy was more prominent in tumors harboring germline BRCA mutations or other homologous recombination defects.

     In this presentation the pivotal trials of PARP inhibitors in pancreatic adenocarcinoma and other cancers will be summarized. Opportunities for PARP inhibitors in pancreatic adenocarcinoma, including development of predictive biomarkers and design of combination regimens, will be discussed.

台大醫院消化外科國際論壇暨林天祐學術研討會

NTUH International Forum of Digestive Surgery & TY Lin Symposium

2020 台大醫院一般外科忘年會

2020 NTUH General Surgery Celebration Event

Multidisciplinary approach in pancreatic cancer

What

2020一般外科國際論壇暨林天祐學術研討會

When

January 18th, 2020

Where

​台大醫學院 104 講堂

Contact Us

To learn more, don’t hesitate to get in touch

  • White Facebook Icon
  • White Instagram Icon
  • White Twitter Icon
  • White LinkedIn Icon

© 2023 by TIC. Proudly created with Wix.com